# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company develop...
UBS analyst Colin Bristow maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $25 to $4.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintai...
Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.
Stifel analyst Bradley Canino reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Hold and lowers the price target from $5...
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of...